GE HealthCare (Nasdaq: GEHC) announced plans to acquire the remaining 50% stake in Nihon Medi-Physics (NMP) from Sumitomo Chemical, gaining full ownership of the Japanese radiopharmaceutical company. The deal, expected to close in early 2025, will enhance GE HealthCare’s ability to deliver precision care for diseases like Alzheimer’s and Parkinson’s.
Expanding Radiopharmaceutical Capabilities
NMP generates $183 million annually and operates 13 manufacturing facilities in Japan. Its portfolio includes:
- Vizamyl: Alzheimer’s diagnostics.
- Datscan: Parkinson’s and dementia diagnostics.
- Myoview: Heart disease imaging.
“As the third-largest pharmaceutical market, Japan is critical to advancing molecular imaging globally,” said Kevin O’Neill, CEO of GE HealthCare’s Pharmaceutical Diagnostics segment.
By fully integrating NMP, GE HealthCare aims to strengthen its molecular imaging footprint in Asia and expand its role in precision diagnostics.
Follow MEDWIRE.AI for updates on MedTech innovations and acquisitions.
